

Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

<https://marketpublishers.com/r/D28F2C74E628EN.html>

Date: September 2025

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: D28F2C74E628EN

Abstracts

The Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:

Major Highlights

This report delivers a comprehensive overview of the Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

DIABETIC NEPHROPATHY PIPELINE ANALYSIS

- Diabetes is a metabolic disorder characterized by high blood sugar level, which is caused by improper functioning of the pancreas, the organ secreting insulin in the body.
- Diabetic nephropathy is considered a disease of the kidney glomerulus and said to be one of the most notable complications in terms of mortality and morbidity for diabetes patients.
- The disease is mainly characterized by macroalbuminuria. Additionally, diabetic nephropathy can also be caused by imbalanced glomerular filtration rate, proteinuria, and hypertension.
- The kidney's imbalanced glomerular filtration rate is going to build up waste products in the blood and thus, increases protein level in the urine.
- However, major signs and symptoms of diabetic nephropathy in its later stages are the high level of blood urea nitrogen (BUN) and serum creatinine, increased albumin secretion in urine, high blood pressure, ankle and leg swelling, itching, nausea, vomiting, morning weakness, and anemia.
- Diabetic nephropathy is a kidney-related complication of type I diabetes and type II diabetes. It is also known as diabetic kidney disease. Early treatment may prevent the disease or slow down its progression, thereby reducing the chance of complications. Diabetic nephropathy may also lead to kidney failure, which is also called as end-stage kidney disease.
- Kidney failure is a life-threatening condition, and at this stage, the only treatment options are dialysis or the kidney transplant.
- Disease-modifying therapies (DMT) that employ angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used in the treatment of diabetic nephropathy. ACE inhibitors including enalapril, ramipril, lisinopril, and captopril are known to lower the amount of protein in the urine. The combination of ARBs and ACE inhibitors provide greater protection to the kidney compared to their individual action. Major ARBs are candesartan, losartan, and irbesartan.
- The efficacious therapies for diabetic nephropathy remain a major unmet need and weigh in on the anticipated nephroprotective effects that mineralocorticoid receptor antagonists and SGLT-2 inhibitors may offer, as well as the safety risks involved.
- The pipeline molecules that are included in clinical trial development phases are Bardoxolone methyl, Calcitriol, Empagliflozin, Spironolactone, Allopurinol, Ivabradine and so on, which are expected to show diabetic nephropathy market growth over the forecast period.
- The molecules in phase 3 clinical trial development are Pirfenidone, Canagliflozin by Janssen Research & Development, Finerenone (BAY94-8862) by Bayer. It has also

identified that most of these molecules are in the pre-clinical development stage. An appreciable number of molecules have been discontinued from development.

- Overall, the diabetic nephropathy market is showing significant growth because of the increasing incidence of diabetes and obesity in different regions of the world.
- In addition, raising awareness about diabetes and kidney-related disorders, increasing R&D investments in drug discovery and development is also driving the growth of the market. Moreover, precise regulatory requirements and drugs longer approval time, as well as the scarcity of diabetic nephropathy comprehensive therapeutic management, are going to inhibit the growth of diabetic nephropathy market.
- The recent market trends that have been observed in diabetic nephropathy market is increasing the use of combination therapy, which is gaining popularity in diabetic nephropathy market.

I would like to order

Product name: Diabetic Nephropathy – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

Product link: <https://marketpublishers.com/r/D28F2C74E628EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D28F2C74E628EN.html>